Development of a multi-matrix LC–MS/MS method for urea quantitation and its application in human respiratory disease studies

Wang, Jianshuang; Gao, Yang; Dorshorst, Drew; Cai, Fang; Bremer, Meire; Milanowski, Dennis; Staton, Tracy; Cape, Stephanie; Dean, Brian; Ding, Xiao

doi:10.1016/j.jpba.2016.11.001

Cited by 13 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most methods for measuring urea rely on LC-MS 47 and HPLC, 48 NMR, 49 or electrochemical techniques. [50][51][52] Commercially available urea colorimetric assay kits operate over a range of concentrations (0.01-0.1 mM) that is too low for evaluation of sweat.…”

Section: Quantitative Colorimetric Analysismentioning

confidence: 99%

Passive sweat collection and colorimetric analysis of biomarkers relevant to kidney disorders using a soft microfluidic system

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Quantitative Colorimetric Analysismentioning

confidence: 99%

Passive sweat collection and colorimetric analysis of biomarkers relevant to kidney disorders using a soft microfluidic system

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The assay achieved high sensitivity with reported LLOQ for kinin peptide quantification in NLF of 1.9 pmol/L. Therefore, the approach reported herein is the first description of quantitative biotherapeutic bioanalysis in NLF using a hybrid LBA-LC-MS/MS method with concentration normalization via urea correlation (described elsewhere). ,, …”

Section: Discussionmentioning

confidence: 97%

“…Therefore, the approach reported herein is the first description of quantitative biotherapeutic bioanalysis in NLF using a hybrid LBA-LC-MS/MS method with concentration normalization via urea correlation (described elsewhere). 12,13,44 In order to ensure the method was applicable to a very broad patient population, we carefully evaluated various factors that could contribute to interferences and matrix effects. Method performance was not affected by the presence of soluble RBD capture reagent to analyte ratios of up to 9-fold, thus ensuring sufficient capture capacity.…”

Section: ■ Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody Combination

Huang

Bouquet

et al. 2022

Anal. Chem.

View full text Add to dashboard Cite

AZD7442 (tixagevimab [AZD8895]/cilgavimab [AZD1061]) is a monoclonal antibody (mAb) combination in development for the prevention and treatment of coronavirus disease 2019. Traditionally, bioanalysis of mAbs is performed using ligand binding assays (LBAs), which offer sensitivity, robustness, and ease of implementation. However, LBAs frequently require generation of critical reagents that typically take several months. Instead, we developed a highly sensitive (5 ng/mL limit of quantification) method using a hybrid LBA-liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) approach for quantification of the two codosed antibodies in serum and nasal lining fluid (NLF), a rare matrix. The method was optimized by careful selection of multiple reaction monitoring, capture reagents, magnetic beads, chromatographic conditions, evaluations of selectivity, and matrix effect. The final assay used viral spike protein receptor-binding domain as capture reagent and signature proteotypic peptides from the complementarity-determining region of each mAb for detection. In contrast to other methods of similar/superior sensitivity, our approach did not require multidimensional separations and can be operated in an analytical flow regime, ensuring high throughput and robustness required for clinical analysis at scale. The sensitivity of this method significantly exceeds typical sensitivity of ∼100 ng/mL for analytical flow 1D LBA-LC-MS/MS methods for large macromolecules, such as antibodies. Furthermore, infection and vaccination status did not impact method performance, ensuring method robustness and applicability to a broad patient population. This report demonstrated the general applicability of the hybrid LBA-LC-MS/MS approach to platform quantification of antibodies with high sensitivity and reproducibility, with specialized extension to matrices of increasing interest, such as NLF.

show abstract

“…The most effective calibration approach to minimize MEs is through the use of a structural or stable isotope labelled (SIL) internal standard (IS), where the analyte of interest and the IS should undergo the same procedure(s). Recently, Whang and coworkers developed a multi-matrix LC-MS/MS method for the determination of urea in plasma in the context of human respiratory diseases 121 . Two stable-isotope-labelled urea isotopologues, [ 15 N2]-urea and [ 13 C, 15 N2]-urea, were used as the surrogate analyte and the internal standard, respectively, providing the best measurement consistency across different matrices.…”

Section: Matrix Effectsmentioning

confidence: 99%

Current developments in LC-MS for pharmaceutical analysis

Beccaria

Cabooter

2020

Analyst

173

View full text Add to dashboard Cite

show abstract

Development of a multi-matrix LC–MS/MS method for urea quantitation and its application in human respiratory disease studies

Cited by 13 publications

References 23 publications

Passive sweat collection and colorimetric analysis of biomarkers relevant to kidney disorders using a soft microfluidic system

Passive sweat collection and colorimetric analysis of biomarkers relevant to kidney disorders using a soft microfluidic system

Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody Combination

Current developments in LC-MS for pharmaceutical analysis

Contact Info

Product

Resources

About